Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2977-2985

  Mackean, M ^a   Planting, A ^b   Twelves, C ^b   Schellens, J ^b   Allman, D ^b   Osterwalder, B ^b   Reigner, B ^b   Griffin, T ^b   Kaye, S ^b   Verweij, J ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBAMIC ACID DERIVATIVE; DRUG METABOLITE; FLOXURIDINE;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TRANSFORMATION; FEMALE; HUMAN; HYPOTENSION; LEUKOPENIA; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

EID: 0031671094     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2977     Document Type: Article

References (26)

1. Ng JSY, Cameron DA, Leonard RCF: Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev 20:357-364, 1994
2. Hansen RM: 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 9:637-642, 1991
3. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rates. J Clin Oncol 6:896-903, 1992
4. Mori A, Bertoglio S, Guglielmi A, et al: Activity of continuous infusion 5-FU in patients with advanced colorectal cancer clinically resistant to bolus 5-FU. Cancer Chemother Pharmacol 33:179-180, 1993
5. Anderson N, Lokich J: Controversial issues in 5-fluorouracil infusion use. Cancer 70:998-1002, 1992
6. Bollag W, Hartmann HR: Tumour inhibitory effects of a new fluorouracil derivative: 5-Deoxy-5-fluorouridine. Eur J Cancer 16:427-432, 1979
7. Bajetta E, Colleoni M, Rosso R, et al: Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 29A:1658-1663, 1993
8. Kono A, Hara Y, Sugata S, et al: Activation of 5′-DFUR by thymidine phosphorylase in human tumours. Chem Pharm Bull 31:175-178, 1983
9. Schuster D, Heim ME, Decoster G, et al: Phase I-II trial of doxifluridine (5′-DFUR) administered as long-term continuous infusion using a portable pump for advanced colorectal cancer. Eur J Cancer 25:1543-1548, 1989
10. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumour selective activity. Proc Am Assoc Cancer Res 36:407, 1995 (abstr 2426)
11. Kawashima A, Horii I: Comparative 4-week oral toxicity study of capecitabine and 5′-DFUR in cynomolgus monkeys. Roche Research Report J-146′249 1994. Investigational Drug Brochure, Capecitabine. Basel, Switzerland, Hoffmann La Roche, Inc, April 1996
12. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117, 1996
13. Tanaka Y, Eda H, Fujimoto K, et al: Anticachectic activity of 5′-DFUR in a murine tumour cachexia model, colon 26 adenocarcinoma. Cancer Res 50:4528-4532, 1990
14. Ishikawa T, Ura M, Yamamoto T, et al: Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5′-DFUR. Int J Cancer 61:516-521, 1995
15. National Cancer Institute Common Toxicity Criteria. National Cancer Institute, Division of Cancer Treatment. 1991
16. Graham MA, Kaye SB: New approaches in preclinical and cancer pharmacokinetics, in Workman P, Graham MA (eds): Cancer Surveys, vol 17. Pharmacokinetics and Cancer Chemotherapy. Cold Spring Harbor Laboratory Press, 1993, pp 27-49
17. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-FU and its metabolites in plasma, urine and bile. Cancer Res 47:2203-2206, 1987
18. Miller AB, Hoogstraten B, Staquet M, et al: Reporting of results of cancer treatment. Cancer 47:207-214, 1981
19. Reigner B, Verweij J, Dirix L, et al: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998 (in press)
20. Schuller J, Cassidy J, Reigner BG, et al: Tumour selectivity of Xeloda™ in colorectal cancer patients. Proc Am Soc Clin Oncol 16:227A, 1997 (abstr 797)
21. Meropol NG, Budman DR, Creaven PJ, et al: A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumours. Ann Oncol 7:87, 1996 (abstr 298, suppl 1)
22. Taguchi T, Ishitani K, Saitoh M, et al: A Japanese phase I study of continuous twice-daily treatment with capecitabine in patients with advanced and/or metastatic solid tumours. Ann Oncol 7:87, 1996 (abstr 299, suppl 1)
23. Dirix LY, Bisset D, Van Oosterom AT, et al: A phase I study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic solid cancer. Ann Oncol 7:87, 1996 (abstr 598, suppl 5)
24. Villalona-Calero M, Moczygemba J, Atkins A, et al: Paclitaxelcapecitabine: Results of a dual escalation phase I and pharmacokinetic study. Ann Oncol 7:127, 1996 (abstr 611, suppl 5)
25. Vasey PA, Pronk L, Twelves C, et al: Phase I and pharmacokinetic study of Xeloda™ (capecitabine) in combination with docetaxel. Proc Eur Confer Clin Oncol 9, Hamburg, Germany, September 14-18, 1997 (abstr 1113)
26. Findlay M, Van Cutsem E, Kocha W, et al: A randomised phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227a, 1997 (abstr 798)